8FR TURBO - TANDEM SYSTEM

K112032 · Spectranetics Corp. · DQY · Oct 17, 2011 · Cardiovascular

Device Facts

• Record ID: K112032
• Device Name: 8FR TURBO - TANDEM SYSTEM
• Applicant: Spectranetics Corp.
• Product Code: DQY · Cardiovascular
• Decision Date: Oct 17, 2011
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.1250
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Turbo-Tandem® System is indicated for atherectomy of infrainguinal arteries.

Device Story

Turbo-Tandem® System consists of laser atherectomy catheter constrained within guiding catheter; guiding catheter features angled biasing tip to offset laser catheter from vessel lumen center for circumferential positioning. Laser catheter uses multiple optical fibers around 0.014" guidewire lumen; connects to Spectranetics CVX-300® Excimer Laser System via optical coupler. Physician operates device in clinical setting; handle includes six-position locking mechanism to adjust laser catheter position on biasing tip ramp. Device facilitates laser ablation of arterial plaque; output is laser energy delivery to target tissue. Benefits include controlled, circumferential vessel treatment. Single-use, sterile device.

Clinical Evidence

Bench testing only. No clinical data presented. Testing included dimensional analysis, in vitro tip position functional testing, in vitro performance testing, laser ablation performance testing, physical testing, and accelerated aging.

Technological Characteristics

8Fr percutaneous guide catheter with integrated laser atherectomy catheter. Features braided shaft with hydrophilic coating, angled biasing tip with radiopaque markers, and six-position locking handle. Laser catheter uses multiple optical fibers; compatible with 0.014" guidewire. Energy source: Spectranetics CVX-300® Excimer Laser System. Sterile, single-use.

Indications for Use

Indicated for atherectomy of infrainguinal arteries in patients requiring peripheral vascular intervention.

Regulatory Classification

Identification

A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.

Predicate Devices

• Spectranetics 7Fr Turbo-Tandem® System (K094036)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the word "Spectranetics" in a stylized font. The text is white against a black background. The word appears to be slightly italicized, and there is a small apostrophe after the "s".

OCT 17 201

Ki 12032
p. 1 of 2

# 510(k) Summary

(As Required By 21 CFR 807.92)

This 510(k) Summary of safety and effectiveness for the Spectranetics 8Fr Turbo-Tandem® System is submitted in accordance with the requirements of the SMDA 1990 and following guidance concerning the organization and content of a 510(k) summary.

#### Submitter Information

| Company name: | Spectranetics Corporation |
|------------------|----------------------------|
| Company address: | 9965 Federal Drive |
| | Colorado Springs, CO 80921 |
| Company phone: | [phone] |
| | [phone] |
| Company fax: | [phone] |

#### Device Identification

| Device trade name: | 8Fr Turbo-Tandem® System |
|------------------------------------|-------------------------------------------------------------|
| Device common name: | Percutaneous guide catheter with laser atherectomy catheter |
| Classification: | Catheter, percutaneous |
| Device class: | Class II (per 21 CFR 870.1250 and 870.4875) |
| Device code: | DQY and MCW |
| Establishment Registration number: | 3007284006 |

#### Performance Standards

There are no performance standards applicable to this device.

#### Device Description

The Turbo-Tandem® System (Laser Guide Catheter with Laser Atherectomy Catheter) is a laser atherectomy catheter constrained within a guiding catheter to facilitate the offset (biased position) of the laser atherectorny catheter. Specifically, the guiding catheter portion of the Turbo-Tandem® System includes an angled biasing tip to offset the distal end of the incorporated laser catheter from the central plane of the vessel lumen allowing for circumferential guidance and positioning of the laser catheter within the vessel.

The incorporated laser catheter of Turbo-Tandem® System is constructed of multiple optical fibers arranged circumferentially around a 0.014" (0.35mm) guidewire compatible lumen and has a fiber optic surface area similar to a 2.0mm laser catheter. The laser catheter has a radiopaque marker bands at the distal tip. The laser catheter is connected to the Spectranetics CVX-300® Excimer Laser System by means of an optical coupler and tail-tubing. ﺮ ﺍﻟﻤﺮﺍﺟﻊ ﺍﻟﻤﺮﺍﺟﻊ ﺍﻟﻤﺮﺍﺟﻊ ﺍﻟﻤﺮﺍﺟﻊ ﺍﻟﻤﺮﺍﺟﻊ

{1}------------------------------------------------

The guiding catheter portion of the Turbo-Tandem® System is comprised of a handle with an incorporated flush port, a braided shaft with hydrophilic coating, and a biasing tip with two radiopaque marker bands. The handle features a six-position locking mechanism to position the laser catheter on the ramp of the biasing tip.

The Turbo-Tandem® System is provided sterile and is intended to be single-use.

#### Indication for Use

The Turbo-Tandem® System is indicated for atherectomy of infrainguinal arteries.

#### Substantially Equivalent Device

The Spectranetics 7Fr Turbo-Tandem® System (K094036) is the predicate device to the 8Fr Turbo-Tandem System. The 8Fr Turbo-Tandem System is similar to the predicate device with regards to design, the only change being the size of the biasing tip (7Fr to 8Fr). The IFU have been modified to specify instructions for both the 7Fr and 8Fr models.

The intended use, intended patient population, and mode of operation are comparable to the predicate device. The materials of construction, packaging, biocompatibility, sterilization, and shelf-life are identical to the predicate device.

#### Summary of Studies

Spectranetics performed device integrity testing to support the claim that the 8Fr Turbo-Tandem System is substantially equivalent to the predicate device integrity tests for the Spectranetics 8Fr Turbo-Tandem System met the specified requirements which consisted of:

- . Dimensional test
- In vitro tip position functional test .
- In vitro performance test .
- . Laser ablation performance test
- Physical test
- Accelerated age test .

### Conclusion

Numerous similarities support a determination of substantial equivalence to the 7Fr Turbo-Tandem. Based on data and information presented, it can be concluded that the 8Fr Turbo-Tandem that the device is as safe, as effective, and performs as well as or better than the predicate device.

{2}------------------------------------------------

#### DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines.

#### Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20995-0002

OCT 1 7 2011

Spectranetics Corporation c/o Shelley Wilcox Senior Regulatory Affairs Specialist 9965 Federal Dr. Colorado Springs, CO 80921

Re: K112032

Trade/Device Name: 8Fr Turbo-Tandem System Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: DQY, MCW Dated: July 14, 2011 Received: July 15, 2011

Dear Ms. Wilcox:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. However, we remind you that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it nuay be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

Page 2 - Ms. Shellev Wilcox

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable. the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industrv/default.htm.

Sincerely vours.

/UU

Ja Bram Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

## Indications for Use

510(k) Number (if known): FBB- K 川谷 O3 ス

Device Name: 8Fr Turbo-Tandem® System

Indications For Use:

The Turbo-Tandem® System is indicated for atherectomy of infrainguinal arteries.

| Prescription Use | X |
|-----------------------------|---|
| (Part 21 CFR 801 Subpart D) | |

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrenge of CDRH, Office of Device Evaluation (ODE)

(Divisior Sign-Off) Division of Cardiovascular Devi

510(k) Number C112032

Page 1 of 1